Measles, mumps, and rubella vaccine in genital warts: A case report of two patients

Meena, Durga Shankar; Sharma, Smily; Chauhan, Payal

doi:10.4103/ijstd.ijstd_44_16

Cited by 11 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding side effects in Group B, this study showed that pain on the day of injection occurred in only 16.7% of patients in Group B. Their pain was tolerable and did not affect the compliance of patients to continue the treatment protocol; this was in agreement with several previous studies (9,11,23,25). In our study, flu-like symptoms were not reported in Group B, and this was in agreement with the findings by Na et al (21).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Intralesional injection of Candida albicans antigen versus measles, mumps, and rubella vaccine for treatment of plantar warts

Rageh¹,

Hewedy²,

Hegab³

2021

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

Introduction: Many therapeutic modalities have been used for management of plantar warts; however, no optimal treatment with high efficacy and no or low recurrence has been explored to date. Intralesional immunotherapy has shown promising results in the treatment of different types of warts. Here we compare the efficacy of Candida albicans-specific antigen versus measles, mumps, and rubella (MMR) vaccine for treatment of plantar warts by intralesional injection. Methods: Sixty patients with refractory or recurrent plantar warts were randomly divided into two equal groups. Group A was treated with C. albicans antigen and Group B with MMR vaccine. Both groups were injected intralesionally in a single wart every 3 weeks until complete clearance of the wart or for a maximum of five sessions. The patients were followed up for an additional 2 months. Results: C. albicans antigen yielded a statistically significant higher cure rate (80.0%) than MMR vaccine (26.7%) in the treatment of plantar warts through a mean of 3.98 sessions versus 4.24 sessions, respectively (p = 0.002), and both modalities were well tolerated, with no remarkable side effects and no recurrence in cured patients during follow-up. Conclusions: Intralesional C. albicans antigen injection is an easy and effective treatment tool for plantar warts, even resistant and recalcitrant ones, with no post-procedural downtime and only transient occasional side effects. MMR vaccine is thought to be less effective.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Although MMR vaccine has shown promising results in previous reports when used in common, multiple, and recalcitrant cutaneous warts (11,(20)(21)(22)(23)(24), data on its efficacy in plantar warts are relatively sparse in published literature.…”

Section: Discussionmentioning

confidence: 99%

Intralesional injection of Candida albicans antigen versus measles, mumps, and rubella vaccine for treatment of plantar warts

Rageh¹,

Hewedy²,

Hegab³

2021

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

show abstract

“…One case study described the use of measles, mumps, and rubella (MMR) vaccine in therapy of genital warts ( Figure 1, Table 1). 7 vaccine has been successfully used in the treatment of genital warts.…”

Section: Methodsmentioning

confidence: 99%

“…In the last several years, intralesional immunotherapy has shown promising efficacy in the treatment of anogenital warts and include the use of following therapeutic agents: Bacille Calmette-Guérin vaccine and tuberculin purified protein derivative, mumps vaccine, Candida albicans antigen, Mycobacterium welchii vaccine, Mycobacterium indicus pranii vaccine, MMR vaccine, Trichophyton skin test antigen, etc 1,[7][8][9][10][11][12][13][14][15][16]. Overall, the results of immunotherapy have been highly variable amongst individuals but the method is highly promising because of its activity beyond the injected wart and therefore, a significant number of patients are cured of distant warts.…”

mentioning

confidence: 99%

Immunotherapy of anogenital warts with measles, mumps, and rubella vaccine

Kansal

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Anogenital warts, caused by the human papillomavirus, are a cause of significant discomfort and psychological concern for the patients. Despite the availability of multiple treatment options, they are a challenge to manage and may be quite refractory. An easy-to-use therapeutic method with low adverse event profile and lowrecurrence rate, therefore, remains highly desirable. In this brief paper, an attempt is made to review the intralesional immunotherapy of anogenital warts with measles, mumps, and rubella vaccine.

show abstract

“…Several diseases have been eradicated with the use of vaccines, such as smallpox in humans and rinderpest on animals, along with the near eradication or successful prevention of other viral or bacterial infections [34,35]. However, the development of vaccines against fungal infections remains a challenge, in part due to a lack of knowledge about the mechanisms of protective immunity against fungal infections and the genetic complexity of fungi [5].…”

Section: Vaccine and Immunotherapymentioning

confidence: 99%

Advances in Vaccine Development Against Sporotrichosis

Almeida

2019

Curr Trop Med Rep

View full text Add to dashboard Cite

Purpose of Review To review recent data about the study of the immune response in sporotrichosis and recent progress in the development of an effective human and feline vaccine. Recent Finding The cell wall of Sporothrix is an important source of antigens with the potential to develop vaccines. A major candidate is a 70-kDa glycoprotein (gp70). Our group developed a model of sporotrichosis treatment using the monoclonal against gp70 (mAbP6E7) with good results. We also recently developed a humanized antibody, mAbP6E7, that increased phagocytosis in human monocytes and reduced the fungal burden in a murine model of sporotrichosis. The other importance the study demonstrated is the protective capacity of an enolase-based vaccine and Montanide™ Pet Gel A (PGA) as an adjuvant against S. schenckii. The use of an immunoproteomic approach demonstrated the efficacy of three peptides as a vaccine to promote a protective immune response against sporotrichosis that aid the development of novel therapeutic approaches against fungal infections. Summary Several diseases have been eradicated with the use of vaccines, but the development of vaccines against fungal infections in humans and animals remains a challenge, in part due to a lack of knowledge about the mechanisms of protective immunity against fungal infections and the genetic complexity of fungi. In this review, we discuss recent advances in vaccine development against sporotrichosis.

show abstract

Measles, mumps, and rubella vaccine in genital warts: A case report of two patients

Cited by 11 publications

References 6 publications

Intralesional injection of Candida albicans antigen versus measles, mumps, and rubella vaccine for treatment of plantar warts

Intralesional injection of Candida albicans antigen versus measles, mumps, and rubella vaccine for treatment of plantar warts

Immunotherapy of anogenital warts with measles, mumps, and rubella vaccine

Advances in Vaccine Development Against Sporotrichosis

Contact Info

Product

Resources

About